<DOC>
	<DOCNO>NCT01206660</DOCNO>
	<brief_summary>The objective study demonstrate desoximetasone 0.25 % topical spray effective treatment patient moderate severe plaque psoriasis .</brief_summary>
	<brief_title>Effects Desoximetasone Spray 0.25 % Patients With Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Desoximetasone</mesh_term>
	<criteria>Male nonpregnant , nonlactating female 18 year age old . Have definite clinical diagnosis stable plaque psoriasis involve ≥ 10 % body surface area ( BSA ) . Have combine total lesion severity score ( TLSS ) ≥ 7 Target Lesion . Have plaque elevation score ≥ 3 ( moderate ) Target Lesion . The Target Lesion must area least 5 cm² . Have Physicians Global Assessment ( PGA ) score 3 ( moderate ) 4 ( severe ) baseline overall disease severity . Patient current diagnosis type psoriasis stable plaque psoriasis ( i.e . acute , guttate , erythrodermic , exfoliative pustular psoriasis ) psoriasis kind face scalp require active treatment study . Nonprescription antipsoriatic shampoo allow study apply solely scalp . Patient history psoriasis unresponsive topical corticosteroid therapy . In Investigator 's opinion , patient dermatological condition , atopic contact dermatitis , may interfere clinical assessment sign symptom psoriasis . Patient history allergy sensitivity corticosteroid history drug hypersensitivity intolerance , opinion Investigator , would compromise safety patient result study . Patient treat within 12 week ( five half life , whichever less ) prior first dose study drug biological therapy psoriasis . Patient receive systemic steroid within 4 week first dose study drug . The use inhale intranasal corticosteroid acceptable long usage stable least 2 week prior first dose study drug continue study . Patients use topical antipsoriatic agent kind topical corticosteroid reason within 2 week prior first use study drug . Nonprescription antipsoriatic shampoo use scalp allow study . Receipt drug part research study within 30 day prior first dosing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>